[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia-childhood\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia-childhood":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,80,105,137,163,200],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100586946","lung-ultrasound-for-guiding-antibiotic-use-in-pediatric-pneumonia-100586946",false,"NCT06921993","Lung Ultrasound for Guiding Antibiotic Use in Pediatric Pneumonia","Lung Ultrasound for Antibiotic Stewardship in Community-Acquired Pneumonia: A Randomized Clinical Trial","LUSCAP","Inclusion Criteria:\n\n* Well-appearing, clinically stable patients aged 3 to 10 years, presenting to the pediatric ED with suspected pneumonia based on a combination of signs and symptoms suggestive of lower respiratory tract infection (LRTI), including:\n\n  1. Respiratory Symptoms: Cough, Tachypnea, Dyspnea (Increased work of breathing), Abnormal findings on auscultation.\n  2. Systemic Symptoms: Fever, Hypoxia, Decreased appetite.\n\n     Exclusion Criteria:\n* Neonates and children up to 3 years of age, and children older than 10 years\n* Children aged 3 to 10 years with any of the following factors:\n\n  1. Recent hospitalization (within the past 14 days)\n  2. Prior CXR or any other chest imaging (e.g. CT scan)\n  3. Ongoing antibiotic therapy\n  4. Hemodynamic instability\n  5. Respiratory failure or severe respiratory distress and\u002For hypoxemia, requiring urgent assessment for conditions such as pneumothorax, hemothorax, or other emergency respiratory conditions\n  6. History of aspiration or ab ingestis pneumonia\n  7. Underlying medical conditions predisposing to severe or recurrent pneumonia, including immunodeficiency, chronic corticosteroid use, chronic lung disease, malignancy, sickle cell disease, congenital heart disease, tracheostomy, and neuromuscular disorders affecting respiration","ALL","3 Years","10 Years",{"count":21,"type":22},659,"ESTIMATED","INTERVENTIONAL",[25],"NA","Pneumonia is a major cause of illness and death in children, with an annual incidence of about 3.3 per 1,000 in those under five years old, many requiring hospitalization. The diagnosis is challenging due to the absence of a universally accepted gold standard, leading to variability in emergency settings. Current guidelines recommend diagnosis based on history and physical examination, which do not reliably differentiate pneumonia from other respiratory infections or identify whether it is bacterial or viral in nature. This uncertainty can lead to the unnecessary use of antibiotics.\n\nCommonly used chest X-rays have limitations such as low sensitivity, moderate interobserver reliability, and the inability to distinguish bacterial from viral pneumonia. In contrast, lung ultrasound has shown high sensitivity and specificity for diagnosing pneumonia in children. However, lung ultrasound also cannot reliably distinguish between bacterial and viral causes and might lead to increased antibiotic prescriptions by detecting minor lung consolidations not seen on chest X-rays. Despite these issues, lung ultrasound is widely used in pediatric pulmonary assessment.\n\nThe primary objective of the study is to determine if using lung ultrasound for diagnosing pneumonia in children can reduce antibiotic prescriptions compared to the standard care approach-which mainly relies on clinical diagnosis (often supplemented by chest X-ray and blood tests in selected cases). The secondary objective is to assess how frequently lung ultrasound impacts management decisions during a single clinical visit, beyond the information provided by history and physical examination. The third objective is to compare the diagnostic accuracy of lung ultrasound-supported diagnosis with existing diagnostic methods.\n\nThe study hypothesizes that lung ultrasound results can act as a decision modifier, similar to other clinical tools and examination findings. However, a lack of consensus on specific lung ultrasound parameters and their clinical correlations contributes to variability in managing suspected pneumonia, potentially leading to antibiotic overuse.\n\nEligible participants are children aged three to ten years who are in good general condition and clinically stable, presenting with signs and symptoms of lower respiratory tract infection indicative of pneumonia. Exclusion criteria include children outside the specified age range, those recently hospitalized, those who have undergone prior chest imaging, those already on antibiotic therapy, those with severe clinical instability, and those with underlying conditions predisposing them to severe or recurrent pneumonia. These criteria help ensure that the study population represents general pediatric community-acquired pneumonia cases, avoiding biases from high-risk patients.\n\nThe ultimate goal of this study is to provide evidence on whether lung ultrasound can serve as a reliable tool to guide antibiotic prescriptions, thereby reducing unnecessary antibiotic use in the management of pediatric pneumonia.",[28,29,30,31],"Pneumonia Childhood","Pneumonia","Lung Ultrasound","Antibiotic Stewardship",[29,33,34,35,36],"Children","Pediatrics","Lung ultrasound","point-of-care ultrasound","RECRUITING","2026-04-02",{"date":40,"type":41},"2026-04-03","ACTUAL",{"date":43,"type":41},"2025-04-24",{"date":45,"type":22},"2028-06-30",{"name":47,"class":48},"Meyer Children's Hospital IRCCS","OTHER",18,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":79},"100624827","phase-4-effect-of-vitamin-c-on-length-of-hospital-stay-in-children-with-severe-pneumonia-100624827","NCT07414693","Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia","Efficacy of Vitamin C as an Adjunct to Standard Treatment in Severe Pneumonia in Children Under Five Years of Age: A Clinical Comparison","Inclusion Criteria:\n\n* presenting with severe pneumonia\n* ≤ 48-hours duration\n\nExclusion Criteria:\n\n* Congenital heart disease\n* Children with chronic respiratory illnesses i.e. Asthma, post tuberculosis bronchiectasis and cystic fibrosis\n* Immunosuppressed i.e. primary immune deficiency, malignancy, on steroid therapy","2 Months","59 Months",{"count":60,"type":22},90,[62],"PHASE4","Severe pneumonia is a common and serious illness in young children and often requires hospital admission. This clinical trial aims to find out whether adding vitamin C to standard treatment can reduce the length of hospital stay in children under five years of age admitted with severe pneumonia.\n\nThe main question this study seeks to answer is:\n\nDoes giving vitamin C along with routine treatment help children with severe pneumonia recover faster and go home earlier compared to standard treatment alone?\n\nIn this study, 90 children aged 2 to 59 months who are admitted to the Children's Hospital Multan with severe pneumonia will take part. Severe pneumonia is defined by fast breathing, fever, cough, and one or more danger signs such as difficulty feeding, repeated vomiting, seizures, bluish discoloration of lips, or noisy breathing. Children with chronic lung disease or weakened immunity will not be included.\n\nAfter parental consent, children will be randomly divided into two groups. One group will receive standard treatment only, which includes oxygen therapy and intravenous antibiotics according to hospital protocol. The second group will receive the same standard treatment plus a daily dose of vitamin C. Neither group will receive any experimental or unapproved therapy.\n\nResearchers will closely monitor each child's recovery, including improvement in breathing rate, temperature, oxygen levels, and overall clinical condition. The child will be discharged when the treating physician determines that recovery criteria are met. The number of days spent in the hospital from the start of treatment until discharge will be recorded.\n\nBy comparing the average hospital stay between the two groups, this study aims to determine whether vitamin C is a useful and safe add-on treatment for severe pneumonia in young children. The findings may help improve care and reduce hospital stay for children with severe pneumonia in the future.",[28,65,66],"Vitamin C","Hospital Stay Time",[29,65,68],"Hospital Stay","2026-02-12",{"date":71,"type":41},"2026-02-17",{"date":73,"type":41},"2025-08-28",{"date":75,"type":22},"2026-02-27",{"name":77,"class":78},"Children's Hospital and Institute of Child Health, Multan","OTHER_GOV",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":79},"100621376","optimization-and-testing-of-alrite-a-clinical-decision-support-tool-for-management-of-respiratory-illnesses-in-young-children-in-primary-care-health-facilities-in-uganda-100621376","NCT07369817","Optimization and Testing of ALRITE, a Clinical Decision Support Tool for Management of Respiratory Illnesses in Young Children in Primary Care Health Facilities in Uganda","Inclusion Criteria:\n\n* Healthcare workers employed at each study site with a minimum of 6 months' experience of caring for children with respiratory symptoms in general outpatient care\n* Completed one of the following training programs: medical officer, clinical officer, nurse, midwife\n* proficient in reading and speaking English, one of the official languages of Uganda\n* at least 18 years of age\n\nExclusion Criteria:\n\n* inability to read\u002Fwrite English","18 Years",{"count":88,"type":22},48,[25],"The goal of this study is to pilot test the feasibility of a mobile health clinical decision support tool called ALRITE for the diagnosis and management of acute lower respiratory illnesses in young children in Uganda. Asthma\u002Fwheezing illness, in particular, is underdiagnosed in this setting. The main questions the study aims to answer are:\n\n* Are the intervention structure, processes, outcomes, and implementations strategies feasible to conduct in the desired settings?\n* Does ALRITE increase the diagnosis of wheezing illness among children seen at Ugandan health centers?\n\nResearchers will compare outcomes before and after ALRITE deployment to healthcare workers at 4 Ugandan healthcare centers using an interrupted time series design. Study participants are healthcare workers.\n\nThere will be12 months of baseline data collection (\"baseline period\"), at the beginning of which healthcare workers will be enrolled at each site. Following the baseline period, health workers will receive ALRITE training and will be encouraged but not required to use ALRITE in clinical care for a 6-month intervention period. Health worker participants will fill out surveys and participate in focus group discussions to provide feedback.",[28,92,93,94],"Childhood Asthma","Acute Lower Respiratory Illness","Wheezing Lower Respiratory Illness","NOT_YET_RECRUITING","2026-01-23",{"date":98,"type":41},"2026-01-27",{"date":100,"type":22},"2026-02-01",{"date":102,"type":22},"2027-11-30",{"name":104,"class":48},"University of Washington",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100567641","novel-tools-to-improve-management-of-paediatric-community-acquired-pneumonia---toolcap-100567641","NCT06670833","Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia - ToolCAP","ToolCAP: Novel Tools to Improve Management of Paediatric Community-Acquired Pneumonia","ToolCAP","Inclusion Criteria:\n\n* Cough OR Difficulty Breathing AND,\n* One of the below:\n\nFast breathing (tachypnoea) \\> 50\u002Fminute (2-12 months) \\> 40\u002Fminute (1-\\\u003C5 years) \\> 25\u002Fminute (5-12 years) OR Lower chest wall indrawing\n\nExclusion Criteria:\n\n* Presenting for repeat visit\u002Ffollow-up of a treated lower respiratory tract infection (index illness \u002F non-acute) or enrolled in the study within the preceding 28 days.\n* Received antibiotic treatment for more than 48 hours at the time of enrolment.\n* WHO IMCI danger signs (inability to drink\u002Fbreastfeed, vomiting everything, convulsions with this illness, lethargy\u002Funconscious).\n* Presence of jaundice.\n* Hypoxaemia with oxygen saturation (SpO2) \\\u003C88%\n* Oxygen saturation (SpO2) \\\u003C90% (or country-specific \u002F altitude-adjusted thresholds) i) With signs of severe respiratory distress (such as nasal flaring, grunting, etc.) OR ii) In children \\\u003C 6 months\n* Requiring non-invasive ventilatory support (i.e., high-flow, bilevel positive airway pressure (BiPAP) and continuous positive airway pressure (CPAP))\n* Underlying disease associated with increased risk of severe pneumonia or pneumonia of unusual aetiology (e.g., WHO acute malnutrition requiring antibiotics as per local guidelines, severe immunodeficiency)\n* HIV positive participant that is either i) less than 12 months old; OR ii) requires admission for this illness; OR iii) known to be uncontrolled on treatment (with a documented VL \\>1000c\u002Fml in the previous 6 months)\n* Caregiver unavailable at the time of enrolment, or unwilling, to provide informed consent.","60 Days","12 Years",{"count":116,"type":22},3500,[25],"The ToolCAP study aims to see if using ultrasound to look at the lungs when children have symptoms of a lung infection will safely allow doctors to improve how they treat those infections. The study will also look at if it's possible to improve how doctors decide which children need antibiotics.\n\n* Lung infections are the most common reason for children to go to the clinic\u002Fhospital.\n* Doctors usually give an antibiotic to every child with a lung infection.\n* Lung infections can be caused by 2 different types of germs - bacteria or viruses.\n* Antibiotics only work against bacteria and not against viruses. Lung infections caused by viruses don't need antibiotics as the body fights them by itself.\n* Lots of research now shows that only 1 in 4 children with a lung infection actually needs an antibiotic, as the rest only have a viral infection causing the symptoms.\n* This means that 3 in 4 children get an antibiotic when they don't need it.\n* Taking too many antibiotics can cause problems for children as it can cause diseases like diabetes or asthma.\n* Nowadays, due to too many people using too many antibiotics, experts are starting to worry that bacteria are starting to become resistant (stronger than the antibiotic).\n* Ultrasound of the lungs appears to be a way of safely looking at the lungs to see if there is an infection and may help doctors better decide who needs an antibiotic.\n\nThis study includes children aged 2 months-12 years who come to the hospital with a lung infection. Children who are very unwell or who have already had 2 days of antibiotic treatment will not be allowed to be in the study.",[29,28,120,34,121,122],"Pneumonia - Bacterial","LRTI","IMCI Guidelines",[124,125,126],"Lung ultrasound (LUS)","Lung auscultation","Pediatric pneumonia","2025-06-17",{"date":129,"type":41},"2025-06-18",{"date":131,"type":41},"2025-04-04",{"date":133,"type":22},"2026-12",{"name":135,"class":48},"University of Bern",9,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":114,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":79},"100589091","phase-1-the-role-of-melatonin-as-an-adjuvant-therapy-in-childhood-pneumonia-100589091","NCT06949904","The Role of Melatonin as an Adjuvant Therapy in Childhood Pneumonia","Inclusion Criteria:\n\n* 1 month to 12 years\n* Both genders\n* Patient diagnosed as having pneumonia or severe pneumonia according to WHO definition\n\nExclusion Criteria:\n\n* Hospitalized within 14 days prior to the study\n* Known TB exposure\n* Active varicella or herpes simplex infection\n* Allergy to the study medication\n* Currently taking melatonin\n* Any non pneumonia acute medical illness which requires antibiotic treatment as per local standard of care\n* Galactose intolerance, the lapp-lactase deficiency or glucose-galactose malabsorption\n* Significant co-morbid disease: lung, cardiac, immune, liver, endocrine, neurological or psychiatric","1 Month",{"count":145,"type":22},60,[147,148],"PHASE1","PHASE2","The goal of this study is to compare the mean length of hospital stay between children with pneumonia receiving melatonin as an adjuvant therapy and those receiving standard of care alone.\n\nThe hypothesis is that combining oral melatonin with standard treatment can reduce the length of hospital stay as compared to standard of care alone.\n\nThe control group will receive standard treatment (antibiotic) while the intervention group will receive standard treatment plus melatonin for 14 days.",[28],[29,152,153],"Childhood pneumonia","Melatonin","2025-04-25",{"date":156,"type":41},"2025-04-29",{"date":158,"type":22},"2025-05",{"date":160,"type":22},"2026-01",{"name":162,"class":48},"Mian Muhammad Hassan Ahmed",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":170,"maxAge":171,"enrollmentInfo":172,"targetDuration":174,"studyType":175,"phases":4,"briefSummary":176,"conditions":177,"keywords":183,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":79},"100583234","validation-of-the-eq-5d-y-3l-and-eq-5d-y-5l-for-paediatric-patients-in-china-100583234","NCT06873672","Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China","Using EQ-5D-Y to Measure the Health of Patients for Multiple Paediatric Health Conditions: a Project to Validate the Self-complete, Interviewer-administered and Proxy Administered Versions of EQ-5D-Y-3L and EQ-5D-Y-5L in China","Inclusion Criteria:\n\n* Children (Patients)\n\n  1. Age: 5-16 years old.\n  2. Diagnosis: Clinically confirmed diagnosis of one of the following conditions:\n\n     Pneumonia (hospitalized due to community-acquired pneumonia); Central Nervous System (CNS) Solid Tumours (receiving active treatment or in post-treatment follow-up); Immune Thrombocytopenic Purpura (ITP) (diagnosed with acute or chronic ITP).\n  3. Health Status: Cognitively and physically capable of completing HRQoL assessments (for self-complete versions).\n  4. Language Proficiency: Able to understand and communicate in Mandarin Chinese.\n  5. Consent: Written informed consent obtained from the primary caregiver and verbal or written assent from the child (if age-appropriate).\n* Caregivers (Parents\u002FFamily Caregivers)\n\n  1. Primary Caregiver: Must be a parent or a long-term family caregiver (e.g., grandparent, older sibling, aunt, or uncle).\n  2. Involvement: Directly responsible for the daily care and medical decision-making of the child.\n  3. Language Proficiency: Able to understand and complete both the self-complete and proxy-reported HRQoL assessments in Mandarin Chinese.\n  4. Consent: Willing to provide informed consent for participation.\n\nExclusion Criteria:\n\n* Children (Patients)\n\n  1. Severe Cognitive or Developmental Impairment: Diagnosed with intellectual disability, autism spectrum disorder, or any neurological condition that prevents understanding and completing HRQoL assessments.\n  2. Severe Physical Disability:\n\n     Conditions that make it impossible to respond to surveys (e.g., advanced neuromuscular disease, severe paralysis).\n  3. Comorbidities: Presence of another major chronic illness that could significantly affect HRQoL measurement (e.g., severe congenital heart disease, uncontrolled epilepsy).\n  4. Recent Participation in Similar Studies:\n\n     If the child has participated in another HRQoL validation study within the past 6 months.\n  5. Inability to Complete Study Follow-Up: Expected to be transferred to another hospital or relocated during follow-up.\n* Caregivers (Parents\u002FFamily Caregivers)\n\n  1. Not the Primary Caregiver:\n  2. Individuals who do not have daily caregiving responsibilities for the child.\n\n     Cognitive Impairment or Severe Health Conditions:\n  3. Caregivers with severe mental illness, dementia, or a medical condition that affects their ability to complete surveys.\n  4. Language Barrier: Unable to understand and complete HRQoL assessments in Mandarin Chinese.\n  5. Refusal to Participate: Caregivers who decline to provide informed consent.","5 Years","16 Years",{"count":173,"type":22},360,"2 Weeks","OBSERVATIONAL","The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China. The main research questions focus on comparing the psychometric performance of EQ-5D-Y-3L and EQ-5D-Y-5L, evaluating the differences between self-complete (SC), interviewer-administered (IA), and proxy-administered (Proxy) versions, and assessing their validity against other HRQoL measures like PedsQL. The study will recruit 360 inpatient-caregiver dyads from three disease groups, i.e., pneumonia, paediatric central nervous system (CNS) solid tumours, and immune thrombocytopenic purpura (ITP), using cross-sectional and longitudinal surveys. Baseline assessments will be conducted at hospital admission, with follow-up at hospital discharge (within 14 days). A qualitative component will explore acceptability and interpretation of EQ-5D-Y. The findings will contribute to the methodological development of EQ-5D-Y, with potential implications for HRQoL measurement and economic evaluations in paediatric healthcare.",[178,179,28,180,181,182],"Quality of Life (QOL)","Patient-Reported Outcome Measures (PROMs)","Neuroblastoma (NB)","Wilms Tumour","Immune Thrombocytopenic Purpura ( ITP )",[184,185,186,187,188,189,190],"Quality of life","children","psychometric measurements","Paediatric pneumonia","Paediatric central nervous system solid tumour","paediatric immune thrombocytopenic purpura","spillover effect","2025-03-07",{"date":193,"type":41},"2025-03-13",{"date":195,"type":22},"2025-04-01",{"date":197,"type":22},"2027-12-31",{"name":199,"class":48},"RenJi Hospital",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":17,"minAge":207,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":23,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":218,"leadSponsor":220,"locationsCount":4},"100560123","thoracic-kt-on-pulmonary-function-ichildren-with-pneumonia-100560123","NCT06573047","Thoracic KT on Pulmonary Function Ichildren with Pneumonia","Effect of Thoracic Kineso Tape on Pulmonary Function in Children with Pneumonia","Inclusion Criteria:\n\n1. Children with age between aged 4 years to 7 years hospitalized with pneumonia and they assemble all the clinical and radiological criteria for pneumonia\n2. Children with normal thoracic spine\n3. Children with stable hemodynamic status\n4. Children with no previous history of thoracic surgery, thoracic deformities rib fracture or any condition that make it difficult to apply the KT.\n\nExclusion Criteria:\n\n1. Children with chest drain\n2. Children with vision or auditory problems\n3. Bone fragility or rib fractures\n4. Children with reports of allergic skin reactions to the use of adhesive bandages, plasters, or other adhesive materials\n5. Children on ventilator\n6. cp children","4 Years","7 Years",{"count":210,"type":22},40,[25],"This study aimed to investigate the effect of thoracic kinesio-tape on Pulmonary Functions, time to clinical resolution and respiratory rate and arterial oxygen saturation in children with pneumonia.\n\nThirty children with pneumonia from both sexes with age ranged from 4 to 7 years participated in this study. The patients were divided into two equal groups (study and control groups), control group received selected chest physiotherapy exercise. Study group received the same selected physical therapy program given to control group in addition to thoracic kinesio-tape three days per week for two weeks.",[28],"2025-02-10",{"date":216,"type":41},"2025-02-13",{"date":158,"type":22},{"date":219,"type":22},"2025-07",{"name":221,"class":48},"Cairo University"]